Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01170962




Registration number
NCT01170962
Ethics application status
Date submitted
16/07/2010
Date registered
28/07/2010
Date last updated
12/10/2015

Titles & IDs
Public title
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Scientific title
A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy
Secondary ID [1] 0 0
2010-019378-34
Secondary ID [2] 0 0
AI444-011
Universal Trial Number (UTN)
Trial acronym
HEPCAT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis C Virus 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BMS-790052
Treatment: Drugs - BMS-790052
Treatment: Drugs - Placebo
Treatment: Drugs - peginterferon alfa-2a
Treatment: Drugs - ribavirin

Experimental: Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior null responders)

Experimental: Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior null responders)

Experimental: Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior partial responders)

Experimental: Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin - (prior partial responders)

Experimental: Arm 5: Placebo plus peginterferon alfa-2a and ribavirin - (prior partial responders only)


Treatment: Drugs: BMS-790052
Film coated tablet, Oral, 20 mg, once daily, 24 weeks

Treatment: Drugs: BMS-790052
Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks

Treatment: Drugs: Placebo
Film coated tablet, Oral, 0mg, Once daily, 24 weeks

Treatment: Drugs: peginterferon alfa-2a
Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks

Treatment: Drugs: ribavirin
Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Extended Rapid Virologic Response (eRVR)
Timepoint [1] 0 0
Week 4, Week 12
Primary outcome [2] 0 0
Percentage of Participants With 24-week Sustained Virologic Response (SVR24)
Timepoint [2] 0 0
Follow-up Week 24
Primary outcome [3] 0 0
Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment
Timepoint [3] 0 0
From first dose to last dose plus 7 days, up to 49 weeks
Primary outcome [4] 0 0
Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period
Timepoint [4] 0 0
From day 8 post last dose of treatment up-to Week 72
Secondary outcome [1] 0 0
Percentage of Participants With Rapid Virologic Response (RVR)
Timepoint [1] 0 0
Week 4
Secondary outcome [2] 0 0
Percentage of Participants With Complete Early Virologic Response (cEVR)
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)
Timepoint [3] 0 0
Follow-up Week 12
Secondary outcome [4] 0 0
Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
Timepoint [4] 0 0
Baseline to follow-up Week 48
Secondary outcome [5] 0 0
Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
Timepoint [5] 0 0
Baseline to follow-up Week 48

Eligibility
Key inclusion criteria
- Subjects chronically infected with HCV genotype 1

- Non-responder to prior therapy with peginterferon alfa and ribavirin

- HCV RNA viral load of 100,00 IU/mL

- Results of a liver biopsy = 24 months prior to randomization consistent with chronic
HCV infection; for compensated cirrhotics can be any time prior to randomization
(compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study
population)

- Ultrasound, CT scan or MRI results 12 months prior to randomization that do not
demonstrate hepatocellular carcinoma

- Body Mass Index (BMI) of 18 to 35 kg/m2
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening

- Evidence of medical condition associated with chronic liver disease other than HCV

- Evidence of decompensated cirrhosis based on radiologic criteria or biopsy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2010
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2012
Sample size
Target
Accrual to date
Final
512
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - Randwick
Recruitment hospital [2] 0 0
Local Institution - Clayton
Recruitment hospital [3] 0 0
Local Institution - Heidelberg
Recruitment hospital [4] 0 0
Local Institution - Prahan
Recruitment hospital [5] 0 0
Local Institution - Fremantle
Recruitment hospital [6] 0 0
Local Institution - Perth
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3084 - Heidelberg
Recruitment postcode(s) [4] 0 0
3004 - Prahan
Recruitment postcode(s) [5] 0 0
6160 - Fremantle
Recruitment postcode(s) [6] 0 0
6001 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Louisiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Oklahoma
Country [14] 0 0
United States of America
State/province [14] 0 0
Pennsylvania
Country [15] 0 0
United States of America
State/province [15] 0 0
Rhode Island
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Wisconsin
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Santa Fe
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
British Columbia
Country [24] 0 0
Canada
State/province [24] 0 0
Ontario
Country [25] 0 0
Denmark
State/province [25] 0 0
Aarhus
Country [26] 0 0
Denmark
State/province [26] 0 0
Hvidovre
Country [27] 0 0
Denmark
State/province [27] 0 0
Odense
Country [28] 0 0
France
State/province [28] 0 0
Clichy Cedex
Country [29] 0 0
France
State/province [29] 0 0
Creteil Cedex
Country [30] 0 0
France
State/province [30] 0 0
Lyon Cedex 04
Country [31] 0 0
France
State/province [31] 0 0
Nice Cedex 03
Country [32] 0 0
France
State/province [32] 0 0
Paris Cedex 14
Country [33] 0 0
France
State/province [33] 0 0
Paris Cedex
Country [34] 0 0
France
State/province [34] 0 0
Vandoeuvre Les Nancy
Country [35] 0 0
Germany
State/province [35] 0 0
Essen
Country [36] 0 0
Germany
State/province [36] 0 0
Frankfurt
Country [37] 0 0
Germany
State/province [37] 0 0
Hamburg
Country [38] 0 0
Germany
State/province [38] 0 0
Hannover
Country [39] 0 0
Italy
State/province [39] 0 0
Cisanello (pisa)
Country [40] 0 0
Italy
State/province [40] 0 0
Pavia
Country [41] 0 0
Mexico
State/province [41] 0 0
Jalisco
Country [42] 0 0
Mexico
State/province [42] 0 0
Morelos
Country [43] 0 0
Mexico
State/province [43] 0 0
Nuevo Leon
Country [44] 0 0
Puerto Rico
State/province [44] 0 0
Ponce
Country [45] 0 0
Puerto Rico
State/province [45] 0 0
San Juan
Country [46] 0 0
Sweden
State/province [46] 0 0
Gothenburg
Country [47] 0 0
Sweden
State/province [47] 0 0
Stockholm

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a
and ribavirin can result in higher cure rates in patients who previously failed therapy and
may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01170962
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01170962